Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells

Moon,Sung Ung; Kang,Mi Hyun; Sung,Ji Hea; Kim,Jin Won; Lee,Jeong Ok; Kim,Yu Jung; Lee,Keun Wook; Bang,Soo Mee; Lee,Jong Seok; Kim,Jee Hyun

doi:10.3892/or.2014.3582

Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells

Authors:
- Sung Ung Moon
- Mi Hyun Kang
- Ji Hea Sung
- Jin Won Kim
- Jeong Ok Lee
- Yu Jung Kim
- Keun Wook Lee
- Soo Mee Bang
- Jong Seok Lee
- Jee Hyun Kim
View Affiliations

Affiliations: Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Gyeonggi-do 463-070, Republic of Korea
Published online on: November 3, 2014 https://doi.org/10.3892/or.2014.3582
Pages: 185-192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Smad3 and Smad4 are signaling mediators in the transforming growth factor β (TGFβ) pathway and play a major role in the progression and migration of many types of cancers. The TGFβ pathway is correlated with resistance against both targeted and conventional chemotherapeutic drugs. The aim of this study was to determine the effect of Smad3/4 on drug sensitivity in chemotherapy-resistant colorectal cancer (CRC) cells. We isolated the TGFβ-mediated chemoresistant CRC cell line DLD1-5FU-C10, which showed high expression of Smad3/4 and p21. In order to analyze the influence of Smad3/4 on drug sensitivity in DLD1-5FU-C10 cells, we knocked down Smad3/4 using small interfering RNAs (siRNA). The results showed similar drug sensitivity between the DLD1‑5FU-C10 and the DLD1 control cells and reduced p21 expression. In addition, we found a significant increase in the levels of 3 TGFβ downstream factors: interleukin 6 (IL6), plasminogen activator (PLAU) and prostaglandin-endoperoxide synthase 2 (PTGS2). Furthermore, we showed that Smad3/4 regulated the JAK1/STAT3 pathway via IL6 in the chemoresistant CRC cell line. In conclusion, we identified Smad3/4 as a novel drug sensitivity regulator in TGFβ-mediated chemotherapy-resistant CRC cells. Our results suggest that Smad3/4 regulate p-STAT3 signaling by IL6 and p21 and highlight an important role for STAT3 signaling in Smad3/4 regulated drug sensitivity in chemoresistant CRC cells.

View Figures

View References

1	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Wels J, Kaplan RN, Rafii S and Lyden D: Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 22:559–574. 2008. View Article : Google Scholar : PubMed/NCBI
4	Derynck R and Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta. 1333:F105–F150. 1997.PubMed/NCBI
5	Massague J: TGF-beta signal transduction. Annu Rev Biochem. 67:753–791. 1998. View Article : Google Scholar : PubMed/NCBI
6	Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol. 6:597–641. 1990. View Article : Google Scholar : PubMed/NCBI
7	Roberts AB, Anzano MA, Lamb LC, Smith JM and Sporn MB: New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA. 78:5339–5343. 1981. View Article : Google Scholar : PubMed/NCBI
8	Sinha S, Nevett C, Shuttleworth CA and Kielty CM: Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. Matrix Biol. 17:529–545. 1998. View Article : Google Scholar
9	Chen CR, Kang Y and Massague J: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA. 98:992–999. 2001. View Article : Google Scholar : PubMed/NCBI
10	Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
11	Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol. 11:S44–S51. 2001.PubMed/NCBI
12	Wakefield LM and Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12:22–29. 2002. View Article : Google Scholar : PubMed/NCBI
13	Tang B, Vu M, Booker T, et al: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest. 112:1116–1124. 2003. View Article : Google Scholar : PubMed/NCBI
14	Gong J, Ammanamanchi S, Ko TC and Brattain MG: Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res. 63:3340–3346. 2003.PubMed/NCBI
15	Dai M, Al-Odaini AA, Arakelian A, Rabbani SA, Ali S and Lebrun JJ: A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion. Breast Cancer Res. 14:R1272012. View Article : Google Scholar
16	Tsushima H, Kawata S, Tamura S, et al: High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 110:375–382. 1996. View Article : Google Scholar : PubMed/NCBI
17	Sim SH, Kang MH, Kim YJ, et al: P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. BMC Cancer. 14:2412014. View Article : Google Scholar : PubMed/NCBI
18	Derynck R, Zhang Y and Feng XH: Smads: transcriptional activators of TGF-beta responses. Cell. 95:737–740. 1998. View Article : Google Scholar : PubMed/NCBI
19	Miyazono K, ten Dijke P and Heldin CH: TGF-beta signaling by Smad proteins. Adv Immunol. 75:115–157. 2000. View Article : Google Scholar : PubMed/NCBI
20	Montgomery E, Goggins M, Zhou S, et al: Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects. Am J Pathol. 158:537–542. 2001. View Article : Google Scholar : PubMed/NCBI
21	Takenoshita S, Tani M, Mogi A, et al: Mutation analysis of the Smad2 gene in human colon cancers using genomic DNA and intron primers. Carcinogenesis. 19:803–807. 1998. View Article : Google Scholar : PubMed/NCBI
22	Xu J and Attisano L: Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 97:4820–4825. 2000. View Article : Google Scholar : PubMed/NCBI
23	Massague J, Seoane J and Wotton D: Smad transcription factors. Genes Dev. 19:2783–2810. 2005. View Article : Google Scholar : PubMed/NCBI
24	Ulloa L, Doody J and Massague J: Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 397:710–713. 1999. View Article : Google Scholar : PubMed/NCBI
25	Xia W, Chen JS, Zhou X, et al: Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res. 10:3815–3824. 2004. View Article : Google Scholar : PubMed/NCBI
26	Lee S and Helfman DM: Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem. 279:1885–1891. 2004. View Article : Google Scholar
27	Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N and Papavassiliou AG: TGF-beta signalling in colon carcinogenesis. Cancer Lett. 314:1–7. 2012. View Article : Google Scholar
28	Becker C, Fantini MC, Schramm C, et al: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 21:491–501. 2004. View Article : Google Scholar : PubMed/NCBI
29	Zhong Z, Wen Z and Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
30	Lee ES, Ko KK, Joe YA, Kang SG and Hong YK: Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol Lett. 2:115–121. 2011.PubMed/NCBI